Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: Role of antibiotics with antipseudomonal activity

Clinical Infectious Diseases

Volumn 38, Issue 5, 2004, Pages 670-677

  Paramythiotou, Elisabeth ^a,c   Lucet, Jean Christophe ^a,d   Timsit, Jean François ^a,b   Vanjak, Dominique ^a   Paugam Burtz, Catherine ^a   Trouillet, Jean Louis ^a   Belloc, Stéphanie ^a   Kassis, Najiby ^a   Karabinis, Andreas ^c   Andremont, Antoine ^a  

^a BICHAT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d GH Bichat Claude Bernard   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; ISEPAMICIN; NETILMICIN; PIPERACILLIN; STREPTOMYCIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HOSPITALIZATION; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ANTIBIOTIC RESISTANCE; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; PHYSIOLOGY;

AGED; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSEUDOMONAS AERUGINOSA; RISK FACTORS;

EID: 10744233726     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381550     Document Type: Article

References (37)

1. Acar JF. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis 1997; 24 (Suppl 1):S17-8.
2. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996; 275:234-40.
3. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2: Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29:245-52.
4. Centers for Disease Control and Prevention. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001; 29:404-21.
5. Dennesen PJ, Bonten MJ, Weinstein RA. Multiresistant bacteria as a hospital epidemic problem. Ann Med 1998; 30:176-85.
6. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl 2):S146-55.
7. Jones RN, Croco MA, Kugler KC, Pfaller MA, Beach ML. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 2000; 37:115-25.
8. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 1996; 15:281-5.
9. Vincent JL. Microbial resistance: lessons from the EPIC study. European Prevalence of Infection. Intensive Care Med 2000; 26 (Suppl 1):S3-8.
10. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25:1094-8.
11. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-82.
12. Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002; 46:854-8.
13. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34:340-5.
14. Lee SC, Fung CP, Liu PY, et al. Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk factors and outcome. Infect Control Hosp Epidemiol 1999; 20:205-7.
15. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33:1859-64.
16. Philippe E, Weiss M, Shultz JM, Yeomans F, Ehrenkranz NJ. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care 1999; 7:83-7.
17. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-32.
18. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155:1699-704.
19. Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. Multiresistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J Hosp Infect 1998; 39:53-62.
20. Pitten FA, Panzig B, Schroder G, Tietze K, Kramer A. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German university hospital. J Hosp Infect 2001; 47:125-30.
21. Bingen E, Bonacorsi S, Rohrlich P, et al. Molecular epidemiology provides evidence of genotypic heterogeneity of multidrug-resistant Pseudomonas aeruginosa serotype O:12 outbreak isolates from a pediatric hospital. J Clin Microbiol 1996; 34:3226-9.
22. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28:1128-33.
23. Acar J, Carret G, Cavallo JD. Communiqué 1998 du Comité de l'Antibiogramme de la Société Française de Microbiologie. Pathol Biol (Paris) 1998; 46:1-16.
24. Lucet JC, Decre D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis 1999; 29:1411-8.
25. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-63.
26. McCabe WR, Jackson GG. Gram-negative bacteremia II: etiology and ecology. Ann Intern Med 1962; 110:847-55.
27. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981; 9:591-7.
28. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ-system failure. Ann Surg 1985; 202:685-93.
29. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281:67-71.
30. Arruda EA, Marinho IS, Boulos M, et al. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 1999; 20:620-3.
31. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002; 162:1515-20.
32. Cailleaux V, Mulin B, Capellier G, Julliot MC, Thouverez M, Talon D. Epidemiological study of variations in beta-lactam antibiotic susceptibility of Pseudomonas aeruginosa in two intensive care units. J Hosp Infect 1997; 37:217-24.
33. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32:1055-61.
34. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2002; 34:1558-63.
35. Lucet JC, Chevret S, Decre D, et al. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996; 22:430-6.
36. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant enterococcus. Emerg Infect Dis 2002; 8:802-7.
37. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002; 34:1047-54.